One or more metastatic tumors measurable per RECIST Criteria
Measurable disease as per RECIST v. criteria
Must have measurable disease per RECIST v. Response Criteria
INCLUSION CRITERIA FOR REGISTRATION (HER MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of measurable or non-measurable disease by RECIST . is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST . is required
Measurable disease by RECIST . criteria
Have measurable or non-measurable disease per RECIST . criteria for solid tumors and RANO criteria for HGG
Measurable disease by RECIST . criteria
Measurable disease as per RECIST v. criteria
Have measurable disease per RECIST . criteria present
Measurable disease by per RECIST . criteria; radiographic tumor assessment performed within  days of registration.
All patients enrolled will be required to have measurable disease by RECIST . criteria
New or increasing non-bone disease (RECIST . criteria);
Measurable disease by RECIST . criteria
Patients must have measurable disease by RECIST criteria
Have measurable disease per RECIST . criteria present
Have measurable disease per RECIST . or irRECIST criteria present
Measurable disease as per the RECIST criteria v .
Measurable disease according to PET Response Criteria, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
CERITINIB INCLUSION CRITERIA: Measurable disease by RECIST v.
REGORAFENIB INCLUSION CRITERIA: Measurable disease by RECIST v.
ENTRECTINIB INCLUSION CRITERIA: Measurable disease by RECIST v.
Patients must have measurable disease by the Modified RECIST criteria
Measurable disease as per RECIST . criteria.
Patients must have measurable disease per RECIST . criteria; all sites of disease must be evaluated within  weeks prior to randomization
Measurable disease per RECIST . criteria
Have measurable disease per RECIST . criteria
Measurable disease by RECIST . criteria
Progressive measurable disease: using conventional solid tumour criteria RECIST ..
Disease must be measurable by RECIST . criteria
Subjects must have measurable disease by CT or MRI per RECIST . criteria (radiographic tumor assessment performed within  days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST .
Measurable disease per RECIST . criteria
Participants must have measurable disease by RECIST . criteria
Measurable disease as assessed by RECIST . criteria (Appendix A).
Measurable disease as assessed by modified RECIST for MPM and by RECIST . criteria for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid carcinoma
Measurable disease by RECIST . criteria
Measurable disease by RECIST . criteria
Participants in the Phase II portion of the trial must have measurable disease by RECIST . criteria
Breast cancer participants must have measurable disease by RECIST criteria
For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:
Measurable disease by RECIST . criteria.
Measurable disease at screening by RECIST . criteria
Measurable disease by RECIST v. criteria
Measurable disease as assessed by RECIST . criteria (Appendix A).
Measurable disease by RECIST . criteria
Measurable disease as assessed by RECIST . criteria (Appendix A).
Measurable disease on baseline imaging per RECIST . criteria
Patients must have measurable disease by RECIST . criteria
Measurable disease per RECIST . criteria
Measurable disease by RECIST criteria
Measurable disease as per RECIST v. criteria
